In this single-center ambispective cohort of 283 Polish patients with COVID-19–related ARDS requiring invasive mechanical ventilation, cumulative mortality reached 44.5% at four years after ICU ...

EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Updated Phase 3 ARDS Results Continue to Show Mortality Benefit On February 24, 2026, Edesa Biotech, Inc. (NASDAQ:EDSA) announced additional Pha ...

Explore India's neonatal respiratory challenges and how simulation training can enhance preparedness and improve outcomes for newborns.

Acute Respiratory Distress Syndrome (ARDS) remains a major cause of morbidity and mortality in critically ill patients worldwide, despite advances in ...

A 10-month-old boy with a rare bone marrow disorder receives life-saving stem cell transplant at Yashoda Hospitals, Hyderabad ...

Edesa Biotech said that data from a late-stage study of its experimental drug for the treatment of Acute Respiratory Distress ...

Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files provisiona ...

Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in ...

A woman survived a severe infection, leading to the amputation of both hands and legs, after her pet dog licked a minor wound ...

Manjit Sangha, in July 2025, returned home on Sunday afternoon from work feeling unwell. The next morning, she was unconscious and her hands and feet were ice-cold, her lips had turned purple and she ...